Chemotherapy and immunotherapy: A close interplay to fight cancer?

被引：17
作者：
Hanoteau, Aurelie [1 ]
Moser, Muriel [1 ]
机构：
[1] Univ Libre Bruxelles, Dept Mol Biol, Immunobiol Lab, Brussels, Belgium
来源：
ONCOIMMUNOLOGY | 2016年 / 5卷 / 07期
关键词：
Chemotherapy; drug efflux; homeostasis; immunotherapy; IL-7/IL-15; lymphopenia; memory T cells; T-CELL HOMEOSTASIS; ANTITUMOR IMMUNE-RESPONSE; CD4(+) CELLS; IN-VIVO; MEMORY; PROLIFERATION; INTERLEUKIN-7; IL-7; NAIVE; THERAPY;
D O I：
10.1080/2162402X.2016.1190061
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In theory, the immunotherapy of cancer should induce the selective destruction of cancer cells and a long-term specific protection, based on the specificity and memory of immunity. This contrasts with the collateral damages of conventional therapies and their toxic effects on host tissues. However, recent data suggest that chemotherapy may potentiate ongoing immune responses, through homeostatic mechanisms. Massive tumor death, empty "immune" niches and selected cytokines may act as a danger signal, alerting the immune system and amplifying pre-existing antitumor reactivity.
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Patient expectations are better for immunotherapy than traditional chemotherapy for cancer
    Ihrig, Andreas
    Richter, Jenniffer
    Gruellich, Carsten
    Apostolidis, Leonidas
    Horak, Peter
    Villalobos, Matthias
    Grapp, Miriam
    Friederich, Hans-Christoph
    Maatouk, Imad
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (12) : 3189 - 3198
  • [32] Cardiotoxicity induced by chemotherapy and immunotherapy in cancer treatment: a bibliometric analysis
    Zhang, Xi
    Xue, Yanfeng
    Hao, Mingyan
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [33] Targeting key cellular signaling network for cancer chemotherapy and immunotherapy
    Chi, Hao
    Jiang, Lai
    Zhang, Shengke
    Liu, Yunfei
    Yang, Guanhu
    Tian, Gang
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [34] The Interplay between Metabolic Adaptations and Diet in Cancer Immunotherapy
    Tran, Duc
    Beeler, J. Scott
    Liu, Jie
    Wiley, Brian
    Chen, Irenaeus C. C.
    Xin, Zilan
    Kramer, Michael H.
    Batchi-Bouyou, Armel L.
    Zong, Xiaoyu
    Walter, Matthew J.
    Petrone, Giulia E. M.
    Chlamydas, Sarantis
    Ferraro, Francesca
    Oh, Stephen T.
    Link, Daniel C.
    Busby, Ben
    Cao, Yin
    Bolton, Kelly L.
    CLINICAL CANCER RESEARCH, 2024, 30 (15) : 3220 - 3228
  • [35] Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review
    Piao, Mei-Na
    Ma, Xiao-Ting
    Tankere, Pierre
    Liam, Chong-Kin
    Li, Jin-Li
    Wang, Jian-Ping
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (18)
  • [36] Prediction of Prognosis, Immunotherapy and Chemotherapy with an Immune-Related Risk Score Model for Endometrial Cancer
    Wei, Wei
    Ye, Bo
    Huang, Zhenting
    Mu, Xiaoling
    Qiao, Jing
    Zhao, Peng
    Jiang, Yuehang
    Wu, Jingxian
    Zhan, Xiaohui
    CANCERS, 2023, 15 (14)
  • [37] Novel lipometabolism biomarker for chemotherapy and immunotherapy response in breast cancer
    Lei Zhang
    Risheng She
    Jianlin Zhu
    Jin Lu
    Yuan Gao
    Wenhua Song
    Songwang Cai
    Lu Wang
    BMC Cancer, 22
  • [38] Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy
    Chrysostomou, Despoina
    Roberts, Lauren A.
    Marchesi, Julian R.
    Kinross, James M.
    GASTROENTEROLOGY, 2023, 164 (02) : 198 - 213
  • [39] Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer
    Chang, Lele
    Zhang, Xuemei
    Ma, Qian
    Kong, Lingyang
    Yu, Yang
    Tao, Ji
    Li, Qingwei
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (02) : 161 - 170
  • [40] Optimising IL-2 for Cancer Immunotherapy
    Sprent, Jonathan
    Boyman, Onur
    IMMUNE NETWORK, 2024, 24 (01)
12345